Treating Advanced Breast Cancer in the Older Woman
|
|
- Archibald Barrett
- 6 years ago
- Views:
Transcription
1 Review Article [1] October 01, 2006 By Martine Extermann, MD, PhD [2] As half of all breast cancers occur in patients beyond the age of 65 and a quarter beyond the age of 75, a significant number of patients with metastatic breast cancer are elderly. New hormonal therapies, such as aromatase inhibitors, appear to have favorably improved the survival of these patients. Side effects such as osteoporosis or cognitive issues appear manageable. Information specific to elderly patients has recently emerged in the field of chemotherapy for metastatic breast cancer. This article reviews data on anthracyclines, taxanes, capecitabine (Xeloda), gemcitabine (Gemzar), trastuzumab (Herceptin), and bevacizumab (Avastin). For most patients in this setting, sequential single-agent chemotherapy appears at this time to be the preferred course of treatment. here is good news for metastatic breast cancer patients: Their survival is increasing from 27% at 3 years in the early 1990s to 44% in the late 1990s, if they are metastatic at presentation (Figure 1).[1] Although these retrospective data do not allow a clear assessment of causality, it is a reasonable hypothesis that the answer lies in the dramatic increase of treatment options available for this disease and their more widespread application. This article will review to what extent this is also true for the elderly, and how well these drugs are suited to this population. T Page 1 of 8
2 Page 2 of 8
3 As age advances, the proportion of aggressive breast cancers with either high-grade, estrogen-receptor (ER)/progesterone-receptor (PR) negativity, or HER2 overexpression decreases. However, such tumors can still develop even in women who are in their 90s. Although these types of tumors pose a higher risk of relapse, even ER/PR-positive, HER2-negative, and lower-grade tumors can reoccur. In such cases, hormonal therapy should be considered. Hormonal Therapy The improvement in survival during the 1990s pertains mostly to hormone receptor-positive patients, which is good news for older patients and is likely due in large part to the arrival of the aromatase inhibitors in the armentarium. Antiestrogen therapy has few side effects, but two of them are somewhat more relevant to the elderly than to the young. One issue is the risk of osteoporosis with aromatase inhibitors, an issue that was primarily raised in the adjuvant setting.[2] However, since certain women with good-prognosis metastatic cancer may undergo years of treatment, the issue should be kept in mind. A pair of large studies Z-FAST and ZO-FAST (Zometa/-Femara Adjuvant Synergy Trials) are under way to assess whether zoledronic acid (Zometa) can prevent this bone loss. If the results are positive, it will be reassuring news for women with metastatic breast cancer, since the oncologic treatment itself often includes bisphosphonates. The other potential problem is the cognitive impact of hormonal therapy. Much has been published about this issue, with often inconclusive results. A recent British study comparing patients enrolled in the ATAC trial (Arimidex, Tamoxifen, Alone or in Combination) to untreated controls with a neuropsychological battery found a similar negative impact on cognitive function for anastrozole (Arimidex), tamoxifen, or both agents combined.[3] The effect consisted mainly of a mild decrease in processing speed and verbal memory. The history of the cognitive impact of hormonal therapy, from estrogen replacement to antiestrogens, is a long and confused one. If there is any impact, it appears to be minor and should not preclude treatment. Chemotherapy Combination vs Single Agent The debate over combination chemotherapy vs sequential single agents for metastatic breast cancer patients is ongoing. Many studies have failed to show a survival advantage for combination regimens. Many studies also fail to analyze the contribution of the trial agent given subsequently in the noncombination arm. Certain combination regimens, such as docetaxel (Taxotere) and capecitabine (Xeloda), have shown a survival advantage over single agents, such as docetaxel alone.[4] It should be noted, however, that in the latter study, diarrhea was a prominent problem affecting most of the patients. Furthermore, the doses of capecitabine used have been proven too toxic for older women. Whether this agent's effectiveness is maintained at lower doses is unclear. Another example is the combination of carboplatin, paclitaxel, and trastuzumab (Herceptin) over paclitaxel and trastuzumab. Time to disease progression was increased from 6.8 to 11.9 months (P =.006), and overall survival was 33.3 and 42.1 months, respectively (P =.27). Although the difference in survival was not significant, it was greater in HER2 3+ disease, and only 196 patients were included in the study.[5] Moreover, the study focused on younger women. Although HER2 positivity occurs less frequently in the elderly, its presence is still possible in this population. In the author's experience, the oldest patient she treated with a trastuzumab-containing regimen was 91 years old. Carboplatin and paclitaxel, notably if given on a weekly basis, has been shown to be a tolerable regimen in the elderly. When measured with a geriatric evaluation, patients treated with weekly paclitaxel or carboplatin/paclitaxel for various cancers showed improvements in activities of daily living (58%), instrumental activities of daily living (75%), pain (79%), energy (86%), and quality of life (76%).[6] Therefore, such a combination is a reasonable one in a woman with this type of aggressive breast cancer. On the other hand, a modern single-agent therapy might be better than an older combination in this setting. Docetaxel alone provided a better survival than mitomycin and vinblastine.[7] In this author's opinion, for HER2-negative tumors in the elderly, we lack a clear demonstration that multiagent chemotherapy offers more than a higher initial response rate when compared to sequential single modern agents. Although some phase III studies have reported positive results, they have not been reproduced, and given the number of studies conducted in women with metastatic breast cancer, it is difficult to assess whether the result is representative, or whether we have the 1 in 20 studies that will be positive with a P <.05 just by chance. The same precautionary comment applies to studies comparing single agents with each other. Tolerance in General Page 3 of 8
4 With palliative-intent chemotherapy, one has to ask oneself whether the benefits outweigh the harms. How well is chemotherapy tolerated? For all chemotherapy regimens combined, cancer patients 70 and older have around a 50% risk of experiencing either a grade 3 or 4 nonhematologic or a grade 4 hematologic side effect (National Cancer Institute Common Toxicity Criteria [NCI-CTC]).[8] From a functional point of view, however, these side effects appear to be well tolerated, with three-quarters of patients remaining able of normal or near normal activity (Figure 2).[9] Furthermore, that study involved all types of chemotherapy, including CHOP (cyclophosphamide, doxorubicin HCl, vincristine [Oncovin], prednisone). Chemotherapy for metastatic breast cancer tends to be on the low side of the toxicity spectrum.[6] What is the cognitive impact of chemotherapy in older women? Few answers are available, as most cognitive studies have been conducted in younger cohorts of women. However, a recent German study addressed the question.[10,11] With an age cutoff set at 60 years, the investigators found that although elderly patients experience more cognitive side effects in the first few days after initiating chemotherapy, there was no difference at 6 months in the cognitive impact of chemotherapy between young and old subjects. In fact, both groups improved. An American study assessed patients 65 years and older receiving various adjuvant chemotherapies for breast cancer. At 6 months, 48% had no change in cognitive function, 41% worsened, and 11% improved.[12] Review of Individual Drugs In the section below, I will review recent data and experience with agents frequently used to treat metastatic breast cancer. Anthracyclines Anthracyclines are increasingly used in the adjuvant treatment of breast cancer in the elderly.[13,14] Although the number of older patients is still too low to achieve statistical significance in the Early Breast Cancer Trialists' Collaborative Group (EBCTCG) meta-analysis, the effect appears increasingly similar to that obtained in younger postmenopausal women. The role of anthracyclines in metastatic disease is less well defined, but they are effective. In a trial in patients who had not previously received anthracyclines, weekly epirubicin (Ellence) provided better survival than gemcitabine (Gemzar) in women aged 60 years and older.[15] The best schedules appear to be low-dose deliveries, such as weekly epirubicin[16] or liposomal doxorubicin (Doxil).[17] The hazard ratio for cumulative cardiac toxicity (ie, congestive heart failure [CHF]) is 3.28 for patients 65 and older receiving 400 mg/m2 or more of doxorubicin, compared to younger patients.[18] Therefore, given the vast choice of alternative chemotherapies, we advise avoiding the use of anthracyclines for metastatic breast cancer in women who have already received anthracyclines as adjuvant treatment. If these agents do become necessary, one should give a regimen with low cardiac toxicity, and consider the addition of dexrazoxane. Taxanes Weekly paclitaxel administered at a dose of 80 mg/m2 on days 1, 8, and 15 has been assessed in two studies focusing on patients 70 and older.[19,20] Both found the drug to be effective. In the Dutch study, the primary reason for discontinuation was fatigue. In the Italian study, the occurrence of five cardiovascular events was noted in 41 patients. The clearance of unbound paclitaxel decreases with Page 4 of 8
5 age, whether on a weekly or an every-3-week schedule.[21,22] This translates into an increased incidence of grade 3 or 4 neutropenia (with no major infectious consequences, however).[22] Docetaxel every 3 weeks provides better survival than paclitaxel every 3 weeks in metastatic breast cancer patients.[23] Weekly paclitaxel is superior to every-3-week paclitaxel, but no direct comparison has been made between the two regimens in metastatic breast cancer. Weekly paclitaxel is associated with a higher neurotoxicity than every-3-week paclitaxel, and docetaxel weekly is complicated by skin and fatigue problems. All of these effects are items of concern for the elderly. An attractive feature of docetaxel is its very simple pharmacokinetics. It is entirely metabolized by the cytochrome P450 subenzyme CYP3A4. Several methods exist to assess the activity of this enzyme; that activity highly correlates with the area under the concentration-time curve (AUC) of docetaxel, which, in turn, has some correlation with its toxicity.[24-28] There might be a potential for pharmacokinetics-based dose adaptation and a more reliable effectiveness/toxicity ratio in the elderly. Elderly patients, on average, take two drugs that interact with the CYP3A4 enzyme, and as such, a personalized functional assessment is useful in this setting.[29] Capecitabine The availability of capecitabine as an oral chemotherapy is attractive to many patients and physicians. Its safety in the elderly was evaluated recently in a phase II study.[30] After 2 deaths in the first 30 patients treated with 1,250 mg/m2 twice a day, the dose was reduced to 1,000 mg/m2 and well tolerated. These results are in line with the findings of the Cancer and Leukemia Group B (CALGB) study, which compared adjuvant capecitabine with standard AC (doxorubicin [Adriamycin], cyclophosphamide) or CMF (cyclophosphamide, methotrexate, fluorouracil) in women 65 and older, where an optional dose increase to 1,250 mg/m2 was eliminated after the occurrence of two deaths in that group. Therefore, capecitabine should not be given at doses above 1,000 mg/m2 to older women. A Swiss Group of Clinical Cancer Research (SAKK) phase I study combined capecitabine and vinorelbine for women 65 and older with metastatic breast cancer.[31] The maximum -tolerated dose was vinorelbine, 20 mg/m2 on days 1 and 8, and capecitabine, 1,000 mg/m2/d (in two doses) on days 1 through 14 for women with bone involvement, and 1,250 mg/m2/d for women without bone involvement. This is a much lower dose than the one used in the capecitabine/docetaxel trial mentioned earlier. Caution should be exerted when combining capecitabine with another drug in the elderly woman. A powerful way to decrease the side effects from capecitabine is to very systematically calculate creatinine clearance, even in women with a seemingly normal creatinine level. The latest dosage information for capecitabine requires dose reduction as soon as the creatinine clearance decreases below 45 ml/min. That said, with proper dose adjustment, capecitabine can be effective and tolerated even in very old patients, offering the option of a relatively nonhematotoxic treatment. Gemcitabine Gemcitabine is an easily tolerated regimen in the elderly. The dose-limiting toxicity is the hematologic toxicity. This often leads to a regimen of days 1 and 8 every 3 weeks rather than days 1, 8,and 15 every 4 weeks. The dose often has to be reduced from the baseline 1,000 mg/m2. This might be due, in part, to the fact that the half-life of gemcitabine is longer in the elderly and in women, although this has not been formally established by trial data.[32] Targeted Therapies Trastuzumab has been discussed briefly above. One analysis assessed specifically whether age was affecting outcome in the pivotal trastuzumab study.[33] The effect was actually better in older patients. The relative risk of mortality was 0.85 ( ) for patients below age 60, and 0.64 ( ) for those above age 60. Trastuzumab can induce CHF. No specific data regarding this effect are yet available in the elderly. It is important to remember, however, that this type of CHF is different from anthracycline-induced CHF: It easily responds to standard CHF therapy and is reversible.[34] Another targeted therapy is bevacizumab (Avastin), an anti-vegf monoclonal antibody. Two phase III studies of the drug in this setting are available. The first one compared capecitabine therapy with and without bevacizumab. The investigators found slightly more responses with the addition of bevacizumab but no difference in progression-free and overall survival.[35] The other, presented at the 2005 San Antonio Breast Conference, compared paclitaxel with or without bevacizumab and revealed a marked difference in progression-free survival and a difference in overall survival at very short follow-up.[36] As far as the older woman is concerned, these results call for a few comments. First, it appears that Page 5 of 8
6 the chemotherapeutic agent might not be a neutral substrate for the antibody. Paclitaxel has well known antiangiogenic properties, and there may be a synergistic effect between the two drugs. Second, these studies excluded patients with significant cardiovascular conditions. No data are thus far available to assess the safety of the use of bevacizumab in the large group of older patients with significant cardiovascular disease or diabetes. Risks and benefits should be carefully weighted for each patient. Conclusions Many options are available for the treatment of older patients with metastatic breast cancer. Hormonal therapy can provide several years of control, notably in patients with soft-tissue or bone-only disease. Multiple studies demonstrate that chemotherapy is well tolerated. In most cases, I advise sequential single-agent therapy. Although individual studies suggest an advantage for some combinations or agents, these should be reproduced to clarify the best approach in these patients. Disclosures: The author has no significant financial interest or other relationship with the manufacturers of any products or providers of any service mentioned in this article. References: 1. Andre F, Slimane K, Bachelot T, et al: Breast cancer with synchronous metastases: trends in survival during a 14-year period. J Clin Oncol 22: , McCloskey E: Effects of third-generation aromatase inhibitors on bone. Eur J Cancer 42: , Jenkins V, Shilling V, Fallowfield L, et al: Does hormone therapy for the treatment of breast cancer have a detrimental effect on memory and cognition? A pilot study. Psychooncology 13:61-66, O'Shaughnessy J, Miles D, Vukelja S, et al: Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: Phase III trial results. J Clin Oncol 20: , Robert NJ, Leyland-Jones B, Asmar L, et al: Randomized phase III study of trastuzumab, paclitaxel, and carboplatin versus trastuzumab and paclitaxel in women with HER-2 overexpressing metastatic breast cancer: An update including survival (abstract 573). Proc Am Soc Clin Oncol 23:20, Presant CA, Thompson E, Leberthon B, et al: Effects of weekly paclitaxel or paclitaxel plus carboplatin on functionality and symptoms of geriatric patients with cancer as measured by a brief geriatric oncology module: A pilot experience. Cancer 103: , Nabholtz JM, Senn HJ, Bezwoda WR, et al: Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group. J Clin Oncol 17: , Extermann M, Chen H, Cantor AB, et al: Predictors of tolerance to chemotherapy in older cancer patients: a prospective pilot study. Eur J Cancer 38: , Chen H, Cantor A, Meyer J, et al: Can older cancer patients tolerate chemotherapy? A prospective pilot study. Cancer 97: , Eberhardt B, Dilger S, Musial F, et al: Short-term monitoring of cognitive functions before and during the first course of treatment. J Cancer Res Clin Oncol 132: , Eberhardt B, Dilger S, Musial F, et al: Medium-term effects of chemotherapy in older cancer patients. Support Care Cancer 14: , Hurria A, Rosen C, Zuckerman E, et al: Effect of adjuvant chemotherapy (CRx) on the cognitive function of older patients (pts) with breast cancer (BC): Results from a prospective study (abstract 8204). J Clin Oncol 23(16S):779s, Page 6 of 8
7 13. Early Breast Cancer Trialists' Collaborative Group: Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 365: , Fargeot P, Bonneterre J, Roche H, et al: Disease-free survival advantage of weekly epirubicin plus tamoxifen versus tamoxifen alone as adjuvant treatment of operable, node-positive, elderly breast cancer patients: 6-year follow-up results of the French adjuvant study group 08 trial. J Clin Oncol 22: , Feher O, Vodvarka P, Jassem J, et al: First-line gemcitabine versus epirubicin in postmenopausal women aged 60 or older with metastatic breast cancer: A multicenter, randomized, phase III study. Ann Oncol 16: , A prospective randomized trial comparing epirubicin monochemotherapy to two fluorouracil, cyclophosphamide, and epirubicin regimens differing in epirubicin dose in advanced breast cancer patients. The French Epirubicin Study Group. J Clin Oncol 9: , O'Brien ME, Wigler N, Inbar M, et al: Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 15: , Swain SM, Whaley FS, Ewer MS: Congestive heart failure in patients treated with doxorubicin: A retrospective analysis of three trials. Cancer 97: , Del Mastro L, Perrone F, Repetto L, et al: Weekly paclitaxel as first-line chemotherapy in elderly advanced breast cancer patients: A phase II study of the Gruppo Italiano di Oncologia Geriatrica (GIOGer). Ann Oncol 16: , ten Tije AJ, Smorenburg CH, Seynaeve C, et al: Weekly paclitaxel as first-line chemotherapy for elderly patients with metastatic breast cancer. A multicentre phase II trial. Eur J Cancer 40: , Smorenburg CH, ten Tije AJ, Verweij J, et al: Altered clearance of unbound paclitaxel in elderly patients with metastatic breast cancer. Eur J Cancer 39: , Lichtman SM, Hollis D, Miller AA, et al: Prospective evaluation of the relationship of patient age and paclitaxel clinical pharmacology: Cancer and Leukemia Group B (CALGB 9762). J Clin Oncol 24: , Jones SE, Erban J, Overmoyer B, et al: Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol 23: , Yamamoto N, Tamura T, Kamiya Y, et al: Correlation between docetaxel clearance and estimated cytochrome P450 activity by urinary metabolite of exogenous cortisol. J Clin Oncol 18: , Yamamoto N, Tamura T, Murakami H, et al: Randomized pharmacokinetic and pharmacodynamic study of docetaxel: Dosing based on body-surface area compared with individualized dosing based on cytochrome P450 activity estimated using a urinary metabolite of exogenous cortisol. J Clin Oncol 23: , Extermann M, Hutson P, Gaffar Y, et al: Pharmacokinetics of weekly docetaxel in elderly patients: How well can it be predicted? Presented at the 5th Meeting of the International Society of Geriatric Oncology, San Francisco, October 15-16, Fleming M, Baker S, Kelly WK, et al: Pharmacokinetics (pk) of weekly docetaxel in older patients with metastatic cancer. Presented at the 6th Meeting of the International Society of Geriatric Oncology, Geneva, Page 7 of 8
8 28. Bruno R, Vivier N, Veyrat-Follet C, et al: Population pharmacokinetics and pharmacokinetic-pharmacodynamic relationships for docetaxel. Invest New Drugs 19: , Extermann M, Overcash J, Wallace K, et al: Influence of concomitant medications metabolized by cytochrome P-450 on toxicity from chemotherapy. Presented at the International Conference on Geriatric Oncology. Rome, Bajetta E, Procopio G, Celio L, et al: Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women. J Clin Oncol 23: , Hess D, Thurlimann B, Pagani O, et al: Capecitabine and vinorelbine in elderly patients (> or =65 years) with metastatic breast cancer: A phase I trial (SAKK 25/99). Ann Oncol 15: , Lichtman SM, Skirvin JA, Vemulapalli S: Pharmacology of antineoplastic agents in older cancer patients. Crit Rev Oncol Hematol 46: , Fyfe GA, Mass R, Murphy M, et al: Survival benefit of trastuzumab (Herceptin) and chemotherapy in older (age>60) patients (abstract 189). Proc Am Soc Clin Oncol 20:48a, Ewer MS, Vooletich MT, Durand JB, et al: Reversibility of trastuzumab-related cardiotoxicity: New insights based on clinical course and response to medical treatment. J Clin Oncol 23: , Miller KD, Chap LI, Holmes FA, et al: Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23: , Miller KD Wang M, Gralow J, et al: A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer: A trial coordinated by the Eastern Cooperative Oncology Group (E2100). Presented at the 28th San Antonio Breast Cancer Symposium, Source URL: Links: [1] [2] Page 8 of 8
TRANSPARENCY COMMITTEE OPINION. 15 February 2006
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 15 February 2006 Taxotere 20 mg, concentrate and solvent for solution for infusion B/1 vial of Taxotere and 1 vial
More informationAdjuvant Systemic Therapy in Early Stage Breast Cancer
Adjuvant Systemic Therapy in Early Stage Breast Cancer Julie R. Gralow, M.D. Director, Breast Medical Oncology Jill Bennett Endowed Professor of Breast Cancer Professor, Global Health University of Washington
More informationTreatment Options for Breast Cancer in Low- and Middle-Income Countries: Adjuvant and Metastatic Systemic Therapy
Women s Empowerment Cancer Advocacy Network (WE CAN) Conference Bucharest, Romania October 2015 Treatment Options for Breast Cancer in Low- and Middle-Income Countries: Adjuvant and Metastatic Systemic
More informationCancer du sein métastatique et amélioration de la survie Pr. X. Pivot
Cancer du sein métastatique et amélioration de la survie Pr. X. Pivot Date of preparation: November 2015. EU0250i TTP/PFS Comparaisons First line metastatic breast cancer Monotherapy Docetaxel Chan 1999
More informationUse of Taxanes in Older Breast Cancer Patients
SIOG Guidelines Update 2014: Use of Taxanes in Older Breast Cancer Patients Laura Biganzoli Medical Oncology Dept New Hospital of Prato Istituto Toscano Tumori Italy Fundamental steps Task Force (TF) on
More informationNeo-adjuvant and adjuvant treatment for HER-2+ breast cancer
Neo-adjuvant and adjuvant treatment for HER-2+ breast cancer Angelo Di Leo «Sandro Pitigliani» Medical Oncology Unit Hospital of Prato Istituto Toscano Tumori Prato, Italy NOAH: Phase III, Open-Label Trial
More informationAppendix 2. Adjuvant Regimens. AC doxorubin 60 mg/m 2 every 3 weeks x 4 cycles Cyclophosphamide 600 mg/m 2
Appendix 2 Adjuvant Regimens AC doxorubin 60 mg/m 2 every 3 weeks x 4 cycles Cyclophosphamide 600 mg/m 2 CMF IV cyclophosphamide 600 mg/m 2 days 1 & 8 every 4 weeks methotrexate 40 mg/m 2 for 6 cycles
More informationTRANSPARENCY COMMITTEE OPINION. 29 April 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 29 April 2009 NAVELBINE 20 mg, soft capsules B/1 (CIP: 365 948-4) NAVELBINE 30 mg, soft capsules B/1 (CIP: 365 949-0)
More informationCommon disease 175,000 new cases/year 44,000 deaths/year Less than 10% with newly diagnosed at presentation have stage IV disease Chronic disease,
Chemotherapy for Metastatic Breast Cancer: Recent Results HARMESH R. NAIK, MD. Karmanos Cancer Institute and St. Mary Hospital Metastatic breast cancer (MBC) Common disease 175,000 new cases/year 44,000
More informationBreast cancer remains the most common malignancy and the second leading. cause of cancer mortality in women in the United States.
Dr. Andrew Seidman s Commentary I. Breast Cancer Overview Breast cancer remains the most common malignancy and the second leading cause of cancer mortality in women in the United States. The following
More informationNational Horizon Scanning Centre. Bevacizumab (Avastin) in combination with non-taxanes for metastatic breast cancer - first line therapy
Bevacizumab (Avastin) in combination with non-taxanes for metastatic breast cancer - first line therapy December 2007 This technology summary is based on information available at the time of research and
More informationTreatment of HER-2 positive breast cancer
EJC SUPPLEMENTS 6 (2008) 21 25 available at www.sciencedirect.com journal homepage: www.ejconline.com Treatment of HER-2 positive breast cancer Matteo Clavarezza, Marco Venturini * Ospedale Sacro Cuore
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Herceptin) Reference Number: ERX.SPA.42 Effective Date: 07.01.16 Last Review Date: 05/17 Line of Business: Commercial [Prescription Drug Plan] Revision Log See Important Reminder at the
More informationTaxotere * and carboplatin plus Herceptin (trastuzumab) (TCH): the first approved non-anthracycline Herceptin-containing regimen 1
Important data from BCIRG 006 Taxotere * and carboplatin plus Herceptin (trastuzumab) (TCH): the first approved non-anthracycline Herceptin-containing regimen 1 in the adjuvant treatment of HER2+ breast
More informationVision of the Future: Capecitabine
Vision of the Future: Capecitabine CHRIS TWELVES Cancer Research Campaign Department of Medical Oncology, University of Glasgow, and Beatson Oncology Centre, Glasgow, United Kingdom Key Words. Capecitabine
More informationToxicities of Chemotherapy Regimens used in Early Breast Cancer
Toxicities of Chemotherapy Regimens used in Early Breast Cancer CERCIT Workshop February 17, 2012 Carlos H Barcenas, M.D., M.S. Fellow Hematology-Oncology MD Anderson Cancer Center CERCIT Scholar Outline
More informationA Quality Initiative of the Program in Evidence-based Care (PEBC), Cancer Care Ontario (CCO)
Evidence-based Series 1-12: ARCHIVED 2014 A Quality Initiative of the Program in Evidence-based Care (PEBC), Cancer Care Ontario (CCO) The Role of Gemcitabine in the Management of Metastatic Breast Cancer
More informationVinorelbine, methotrexate and fluorouracil (VMF) as first-line therapy in metastatic breast cancer: a randomized phase II trial
Original article Annals of Oncology 14: 699 703, 2003 DOI: 10.1093/annonc/mdg199 Vinorelbine, methotrexate and fluorouracil (VMF) as first-line therapy in metastatic breast cancer: a randomized phase II
More informationClinical Expert Submission Template
Clinical Expert Submission Template Thank you for agreeing to give us a personal statement on your view of the technology and the way it should be used in the NHS. Health care professionals can provide
More informationTJ ISSN Introduction SHORT COMMUNICATION
TJ ISSN 0300-8916 Tumori 2017; 103(1): e4-e8 DOI: 10.5301/tj.5000543 SHORT COMMUNICATION Efficacy and safety of vinorelbine-capecitabine oral metronomic combination in elderly metastatic breast cancer
More informationNadia Harbeck Breast Center University of Cologne, Germany
Evidence in Favor of Taxane Based Combinations and No Anthracycline in Adjuvant and Metastatic Settings Nadia Harbeck Breast Center University of Cologne, Germany Evidence in Favor of Taxane Based Combinations
More informationDifferent adjuvant chemotherapy regimens in older breast cancer patients?
Annals of Oncology Advance Access published January 18, 2015 1 Different adjuvant chemotherapy regimens in older breast cancer patients? Hans Wildiers 1 and Etienne Brain 2 1Department of General Medicine,
More information4/13/2010. Silverman, Buchanan Breast, 2003
Tailoring Breast Cancer Treatment: Has Personalized Medicine Arrived? Judith Luce, M.D. San Francisco General Hospital Avon Comprehensive Breast Care Center Outline First, treatment of DCIS Sorting risk
More informationNon-Anthracycline Adjuvant Therapy: When to Use?
Northwestern University Feinberg School of Medicine Non-Anthracycline Adjuvant Therapy: When to Use? William J. Gradishar MD Betsy Bramsen Professor of Breast Oncology Director, Maggie Daley Center for
More informationKey Words. Adjuvant therapy Breast cancer Taxanes Anthracyclines
The Oncologist Mayo Clinic Hematology/Oncology Reviews Adjuvant Therapy for Breast Cancer: Recommendations for Management Based on Consensus Review and Recent Clinical Trials BETTY A. MINCEY, a,b FRANCES
More informationPaclitaxel in Breast Cancer
Paclitaxel in Breast Cancer EDITH A. PEREZ Mayo Foundation and Mayo Clinic Jacksonville, Jacksonville, Florida, USA Key Words. Paclitaxel Antineoplastic agents Breast neoplasms Clinical trials ABSTRACT
More informationAdjuvant Chemotherapy for Elderly Women with Breast Cancer: Matti S. Aapro, M.D. IMO Clinique de Genolier Switzerland
SIOG Berlin October 2009 Adjuvant Chemotherapy for Elderly Women with Breast Cancer: Immediate Benefit and Long-Term Risk Matti S. Aapro, M.D. IMO Clinique de Genolier Switzerland 1 2 BACKGROUND MESSAGE
More informationFDA APPROVES HERCEPTIN FOR THE ADJUVANT TREATMENT OF HER2-POSITIVE NODE-POSITIVE BREAST CANCER
NEWS RELEASE Media Contact: Kimberly Ocampo (650) 467-0679 Investor Contact: Sue Morris (650) 225-6523 Advocacy Contact: Ajanta Horan (650) 467-1741 FDA APPROVES HERCEPTIN FOR THE ADJUVANT TREATMENT OF
More informationDocetaxel. Class: Antineoplastic agent, Antimicrotubular, Taxane derivative.
Docetaxel Class: Antineoplastic agent, Antimicrotubular, Taxane derivative. Indications: -Breast cancer: -Non small cell lung cancer -Prostate cancer -Gastric adenocarcinoma _Head and neck cancer Unlabeled
More informationAnthracyclines in the elderly breast cancer patients
Anthracyclines in the elderly breast cancer patients Etienne GC Brain, MD PhD Medical Oncology Centre René Huguenin, Saint-Cloud & Group GERICO, FNCLCC, Paris Centre René Huguenin - Saint-Cloud Facts about
More informationBreast Cancer Breast Managed Clinical Network
Initial Evaluation Clinical Stage Pre-Treatment Evaluation Treatment and pathological stage Less than 4 positive lymph nodes Adjuvant Treatment ER Positive HER2 Negative (see page 2 & 3 ) HER2 Positive
More informationCOME HOME Innovative Oncology Business Solutions, Inc.
Innovative Oncology Business Solutions, Inc. Breast Cancer Diagnostic/Therapeutic Pathway V11, April 2015 Required Structured Data Fields: ICD9 Code Stage Staging Components Performance Status Treatment
More informationBest of San Antonio 2008
Best of San Antonio 2008 Ellie Guardino, MD/PhD Assistant Professor Stanford University BIG 1 98: a randomized double blind phase III study evaluating letrozole and tamoxifen given in sequence as adjuvant
More informationTriple Negative Breast Cancer: Part 2 A Medical Update
Triple Negative Breast Cancer: Part 2 A Medical Update April 29, 2015 Tiffany A. Traina, MD Breast Medicine Service Memorial Sloan Kettering Cancer Center Weill Cornell Medical College Overview What is
More informationUpdate from the 25th Annual San Antonio Breast Cancer Symposium December 11 14, 2002
Update from the 25th Annual San Antonio Breast Cancer Symposium December 11 14, 2002 Nearly 5,000 physicians, oncologists, radiologists, epidemiologists, basic scientists, and breast cancer advocates from
More informationBreast Cancer? Breast cancer is the most common. What s New in. Janet s Case
Focus on CME at The University of Calgary What s New in Breast Cancer? Theresa Trotter, MD, FRCPC Breast cancer is the most common malignancy affecting women in Canada, accounting for almost a third of
More informationAdjuvant Chemotherapy + Trastuzumab
Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer Adjuvant Chemotherapy + Trastuzumab (Optimal Drugs / Dosage / Trastuzumab) Adjuvant Chemotherapy (Optimal Drugs / Optimal Dosage
More informationComing of Age: Breast Cancer in Seniors HYMAN B. MUSS
The Oncologist Understanding and Treating Triple-Negative Breast Cancer Across the Age Spectrum Coming of Age: Breast Cancer in Seniors HYMAN B. MUSS The University of North Carolina Lineberger Cancer
More informationOvarian cancer in elderly women
Ovarian cancer Ovarian cancer in elderly women Claire FALANDRY, Michel FABBRO, Olivier GUERIN, Jean-Emmanuel KURTZ, Anne LESOIN. Problem Background Population on the rise and extremely heterogeneous Delayed
More informationDennis J Slamon, MD, PhD
I N T E R V I E W Dennis J Slamon, MD, PhD Dr Slamon is Professor of Medicine, Chief of the Division of Hematology/Oncology and Director of Clinical and Translational Research at UCLA s David Geffen School
More informationClinical Management Guideline for Breast Cancer
Initial Evaluation Clinical Stage Pre-Treatment Evaluation Treatment and pathological stage Adjuvant Treatment Less than 4 positive lymph nodes ER Positive HER2 Negative (see page 2 & 3 ) Primary Diagnosis:
More informationExtending Survival with Chemotherapy in Metastatic Breast Cancer Joyce O'Shaughnessy. doi: /theoncologist
Extending Survival with Chemotherapy in Metastatic Breast Cancer Joyce O'Shaughnessy The Oncologist 2005, 10:20-29. doi: 10.1634/theoncologist.10-90003-20 The online version of this article, along with
More informationChemotherapy With or Without Targeted Drugs* in Metastatic Breast Cancer
Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer Chemotherapy With or Without Targeted Drugs* in Metastatic Breast Cancer * Substances without published evidence based on at
More informationMdi Medical Management of Breast Cancer Morbidity and Mortality Aug 13, 2009 Irina Kovatch, PGY3 Introduction Metastatic disease is the principal cause of death from breast cancer Metastatic events often
More informationChapter. Contents Breast Cancer Adjuvant Epirubicin weekly. Docetaxel Copy No:
Chapter 2: Breast Cancer Contents Chapter 2: Breast Cancer... 1 Breast Cancer... 2 Adjuvant...... 2 Epi-CMF... 2 FEC / docetaxel... 3 FEC100... 4 AC/EC/TC... 4 (neo) adjuvant... 5... 5 HER2 positive: TCarboH...
More informationRelative dose intensity delivered to patients with early breast cancer: Canadian experience
M E D I C A L O N C O L O G Y Relative dose intensity delivered to patients with early breast cancer: Canadian experience S. Raza MD, S. Welch MD, and J. Younus MD ABSTRACT Adjuvant chemotherapy for early
More informationIt is a malignancy originating from breast tissue
59 Breast cancer 1 It is a malignancy originating from breast tissue including both early stages which are potentially curable, and metastatic breast cancer (MBC) which is usually incurable. Most breast
More informationSustained benefits for women with HER2-positive early breast cancer JORGE MADRID BIG GOCCHI PROTOCOLO HERA
Sustained benefits for women with HER2-positive early breast cancer JORGE MADRID BIG GOCCHI PROTOCOLO HERA The fascinating history of Herceptin 1981 1985 1987 1990 1992 1998 2000 2005 2006 2008 2011 Murine
More informationBCCA Protocol Summary for Adjuvant Therapy for Breast Cancer Using Fluorouracil, Epirubicin and Cyclophosphamide
BCCA Protocol Summary for Adjuvant Therapy for Breast Cancer Using Fluorouracil, Epirubicin Cyclophosphamide Protocol Code Tumour Group Contact Physician BRAJFEC Breast Dr. Susan Ellard ELIGIBILITY: Patients
More informationEdith A. Perez, Ahmad Awada, Joyce O Shaughnessy, Hope Rugo, Chris Twelves, Seock-Ah Im, Carol Zhao, Ute Hoch, Alison L. Hannah, Javier Cortes
BEACON: A Phase 3 Open-label, Randomized, Multicenter Study of Etirinotecan Pegol (EP) versus Treatment of Physician s Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously
More information30 TH ANNUAL SAN ANTONIO BREAST CANCER SYMPOSIUM (SABCS) NEW ADVANCES IN THE TREATMENT OF BREAST CANCER
EDUCATIONAL HIGHLIGHTS FROM DATA PRESENTED AT THE 30 TH ANNUAL SAN ANTONIO BREAST CANCER SYMPOSIUM (SABCS) NEW ADVANCES IN THE TREATMENT OF BREAST CANCER DECEMBER 13 16, 2007, SAN ANTONIO, TX, USA 2 CONTENTS
More informationDo we have to change our anti-cancer strategy in case of cardiac toxicity? Guy Jerusalem, MD, PhD
Do we have to change our anti-cancer strategy in case of cardiac toxicity? Point of view of the oncologist Guy Jerusalem, MD, PhD CHU Sart Tilman Liège Anticancer therapy: cardiac toxicity New anticancer
More informationSequential Dose-Dense Adjuvant Therapy With Doxorubicin, Paclitaxel, and Cyclophosphamide
Sequential Dose-Dense Adjuvant Therapy With Doxorubicin, Paclitaxel, and Cyclophosphamide Review Article [1] April 01, 1997 By Clifford A. Hudis, MD [2] The recognition of paclitaxel's (Taxol's) activity
More informationSTUDY FINDINGS PRESENTED ON TAXOTERE REGIMENS IN HEAD AND NECK, LUNG AND BREAST CANCER
Contact: Anne Bancillon + 33 (0)6 70 93 75 28 STUDY FINDINGS PRESENTED ON TAXOTERE REGIMENS IN HEAD AND NECK, LUNG AND BREAST CANCER Key results of 42 nd annual meeting of the American Society of Clinical
More informationClinical Policy: Lapatinib (Tykerb) Reference Number: CP.PHAR.79 Effective Date: Last Review Date: 11.17
Clinical Policy: (Tykerb) Reference Number: CP.PHAR.79 Effective Date: 10.01.11 Last Review Date: 11.17 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationAdjuvant chemotherapy of breast cancer
Journal of BUON 10: 175-180, 2005 2005 Zerbinis Medical Publications. Printed in Greece REVIEW ARTICLE Adjuvant chemotherapy of breast cancer S. Bešlija Department of Medical Oncology, Institute of Oncology,
More informationNew Targeted Agents Demonstrate Greater Efficacy and Tolerability in the Treatment of HER2-positive Breast Cancer
New Evidence reports on presentations given at ASCO 2012 New Targeted Agents Demonstrate Greater Efficacy and Tolerability in the Treatment of HER2-positive Breast Cancer Presentations at ASCO 2012 Breast
More informationHorizon Scanning Centre November Vinflunine (Javlor) monotherapy for advanced breast cancer SUMMARY NIHR HSC ID: 7887
Horizon Scanning Centre November 2012 Vinflunine (Javlor) monotherapy for advanced breast cancer SUMMARY NIHR HSC ID: 7887 This briefing is based on information available at the time of research and a
More informationThe legally binding text is the original French version
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 29 November 2006 TAXOTERE 20 mg, concentrate and solvent for infusion in single-dose vials of 7 ml, individually packed
More informationOvertreatment with systemic treatment - Long term sequelae. Jacques Bonneterre Lille ( France)
Overtreatment with systemic treatment - Long term sequelae Jacques Bonneterre Lille ( France) Why study long term sequelae? Long term sequelae induced by hormonotherapy and chemotherapy ( some might be
More informationJonathan Dickinson, LCL Xeloda
Xeloda A blockbuster in the making Jonathan Dickinson, LCL Xeloda Xeloda unique tumor-activated mechanism Delivering more cancer-killing agent straight into cancer Highly effective comparable efficacy
More informationConsiderations in Adjuvant Chemotherapy. Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology
Considerations in Adjuvant Chemotherapy Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology 80 70 60 50 40 30 20 10 0 EBCTCG 2005/6 Overview Control Arms with No Systemic Treatment
More informationContemporary Chemotherapy-Based Strategies for First-Line Metastatic Breast Cancer
Contemporary Chemotherapy-Based Strategies for First-Line Metastatic Breast Cancer Hope S. Rugo, MD Professor of Medicine Director, Breast Oncology and Clinical Trials Education University of California
More informationAC-DOCE Regimen. AC-DOCE+TRAS Regimen AC-DOCE AC-DOCE+TRAS. A - Regimen Name. Disease Site Breast. Adjuvant. Regimen Category. Evidence-Informed :
Regimen Monograph Regimen Name Drug Regimen Cycle Frequency Premedication and Supportive Measures Dose Modifications Adverse Effects Interactions Drug Administration and Special Precautions Recommended
More informationManagement of Advanced Colorectal Cancer in Older Patients
Review Article [1] April 15, 2005 By Stuart M. Lichtman, MD, FACP [2] Many elderly individuals have substantial life expectancy, even in the setting of significant illness. There is evidence to indicate
More information亞東紀念醫院 Breast Cancer 化學治療處方集
亞東紀念醫院 Breast Cancer 化學治療處方集 2008-08 制定 最近修改日期 :2015-01 CMF Breast cancer 化學治療處方參考集 Adjuvant Classic CMF Cyclophosphamide 100mg/m2 PO qd; D1-D14 Methotrexate 40mg/m 2 in N/S 100 ml IV drip 30 mins; D1,
More informationDisease Update: Metastatic Breast Cancer
Disease Update: Metastatic Breast Cancer Aimee Faso, PharmD, BCOP, CPP Oncology Clinical Specialist, GI/Breast UNC Hospitals and Clinics August 2015 Objectives Identify treatment choices of metastatic
More informationNational Horizon Scanning Centre. Sunitinib (Sutent) for advanced and/or metastatic breast cancer. December 2007
Sunitinib (Sutent) for advanced and/or metastatic breast cancer December 2007 This technology summary is based on information available at the time of research and a limited literature search. It is not
More informationRoohi Ismail-Khan, MD, MS
Roohi Ismail-Khan, MD, MS Associate Member Department of Breast Oncology H. Lee Moffitt Cancer Center Associate Professor University of South Florida Department of Oncological Sciences September 27, 2018
More informationCASE STUDIES CLINICAL CASE SCENARIOS. Matthew J. Ellis, MD, PhD
CLINICAL CASE SCENARIOS Matthew J. Ellis, MD, PhD Clinicians face daily challenges in the management of individual patients with breast cancer who demonstrate different characteristics in terms of estrogen
More informationHighlights. Padova,
Highlights P Pronzato Padova, 17.11.2012 Last 12 Months Main Meetings SABCS 2011 (San Antonio) EBCC 8 2012 (Wien) ASCO 2012 (Chicago) ESMO/ECCO 2012 (Wien) The Medical Oncology Job Risk Manager Strategy
More informationSystemic Therapy Considerations in Inflammatory Breast Cancer
Systemic Therapy Considerations in Inflammatory Breast Cancer Shani Paluch-Shimon, MBBS, MSc Director, Breast Oncology Unit Shaare Zedek Medical Centre, Jerusalem Israel Disclosures Roche: Speakers bureau,
More informationBIOLOGICAL THERAPIES FOR BREAST CANCER Updates from the 2005 San Antonio Breast Cancer Symposium
Emerging trends and recommendations BIOLOGICAL THERAPIES FOR BREAST CANCER Updates from the 2005 San Antonio Breast Cancer Symposium Joseph Ragaz, MD, FRCPC Top-line summary Here, Oncology Exchange presents
More informationOptimal chemotherapy regimen. for older women with breast cancer
Optimal chemotherapy regimen and targeted treatments for older women with breast cancer Etienne Brain, MD, PhD Medical Oncology HÔPITAL RENÉ HUGUENIN Au 1 er janvier 2010, le Centre René Huguenin devient
More informationPRO: Pathologic Complete Response Does Predict Outcome for Early Stage Breast Cancer Patients
PRO: Pathologic Complete Response Does Predict Outcome for Early Stage Breast Cancer Patients Amelia B. Zelnak, M.D., M.Sc. Assistant Professor of Hematology and Medical Oncology Winship Cancer Institute
More informationMetronomic chemotherapy for breast cancer
Metronomic chemotherapy for breast cancer M. Colleoni International Breast Cancer Study Group (IBCSG), Division of Medical Senology, European Institute of Oncology Metronomic Scheduling and Inhibition
More informationAnthracyclines for Breast Cancer? Are Adjuvant Anthracyclines Dispensible? Needs to be Answered in a Large Prospective Trial
Anthracyclines for Breast Cancer? Are Adjuvant Anthracyclines Dispensible? Needs to be Answered in a Large Prospective Trial Joanne L. Blum, MD, PhD Baylor-Sammons Cancer Dallas, TX Early Breast Cancer
More informationBREAST CANCER (RECURRENT OR METASTATIC) TREATMENT REGIMENS (Part 1 of 5)
BREAST CANCER (RECURRENT METASTATIC) TREATMENT S (Part 1 of 5) Clinical Trials: The NCCN recommends cancer patient participation in clinical trials as the gold standard for treatment. Cancer therapy selection,
More informationTrastuzumab (Herceptin) for HER2 positive early, locally advanced and inflammatory breast cancer neoadjuvant treatment
Trastuzumab (Herceptin) for HER2 positive early, locally advanced and inflammatory breast cancer neoadjuvant treatment August 2010 This technology summary is based on information available at the time
More informationLatest News in Breast Cancer Research
Latest News in Breast Cancer Research Highlights from the 2011 San Antonio Breast Cancer Symposium www.cancercare.org This special edition of the CancerCare Connect booklet series highlights cutting-edge
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Verzenio) Reference Number: CP.PHAR.355 Effective Date: 10.24.17 Last Review Date: 05.18 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this
More informationCARDIOVASCULAR CONSIDERATIONS IN THE GERIATRIC PATIENT WITH CANCER
CARDIOVASCULAR CONSIDERATIONS IN THE GERIATRIC PATIENT WITH CANCER MARTINE EXTERMANN, MD, PHD MOFFITT CANCER CENTER, UNIVERSITY OF SOUTH FLORIDA TAMPA, FL, USA JEOPARDY CATEGORIES Age as a risk factor
More informationOPTIMIZING NONANTHRACYLINES FOR EARLY BREAST CANCER. Stephen E. Jones, M.D. US Oncology Research, McKesson Specialty Health The Woodlands, Tx
OPTIMIZING NONANTHRACYLINES FOR EARLY BREAST CANCER Stephen E. Jones, M.D. US Oncology Research, McKesson Specialty Health The Woodlands, Tx ANTHRACYCLINES AND TAXANES ARE COMMONLY USED USED IN MOST REGIMENS
More informationNCCP Chemotherapy Regimen
Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day followed by PACLitaxel (175) 14 day and Trastuzumab Therapy (DD AC-TH) Note: There is an option for Dose Dense DOXOrubicin, cyclophosphamide
More informationAdjuvant treatment for early breast cancer
Annals of Oncology 16 (Supplement 2): ii182 ii187, 2005 doi:10.1093/annonc/mdi709 Adjuvant treatment for early breast cancer I. Smith The Royal Marsden Hospital, London, UK Introduction Survival rates
More informationVI.2 Elements for a Public Summary VI.2.1 Overview of Disease Epidemiology Acute Nausea and Vomiting (N&V) Etiologies:
VI.2 Elements for a Public Summary VI.2.1 Overview of Disease Epidemiology Acute Nausea and Vomiting (N&V) Incidence: The incidence of acute and delayed N&V was investigated in highly and moderately emetogenic
More informationThe absolute benefit from chemotherapy for both older and younger patients appeared most significant in ER-negative populations.
Hello, my name is Diane Hecht, and I am a Clinical Pharmacy Specialist at the University of Texas MD Anderson Cancer Center. It s my pleasure to talk to you today about the role of chemotherapy in this
More informationTrastuzumab (IV) Monotherapy - 7 days
INDICATIONS FOR USE: Trastuzumab (IV) Monotherapy - 7 days Regimen *Reimbursement INDICATION ICD10 Code Status Treatment of patients with HER2 positive metastatic breast cancer (MBC) C50 00201a Hospital
More informationForm 2023 R2.0: Ovarian Cancer Pre-HSCT Data
Key Fields Sequence Number Date Received: - - CIBMTR Center Number: CIBMTR Recipient ID: Today's Date: - - Date of HSCT for which this form is being completed: - - HSCT type: (check all that apply) Autologous
More informationBreast Cancer Basics. Clinical Oncology for Public Health Professionals. Ben Ho Park, MD, PhD
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of that license and the conditions of use of materials on this
More informationMetastatic Breast Cancer What is new? Subtypes and variation?
Metastatic Breast Cancer What is new? Subtypes and variation? Anne Blaes, MD, MS University of Minnesota, Division of Hematology/Oncology Director, Adult Cancer Survivor Program Current estimates for metastatic
More information2
1 2 Systematic review of published evidence PUBMED 1999-2017 ASCO 1999-2017 SABCS 1999-2017 ECCO/ESMO 1999-2017 3 Statement: Anthracycline/ taxane based chemotherapy 1. Budd GT et al. SWOG S0221: A Phase
More informationCardiotoxicity: The View of the Cardiologist
Cardiotoxicity: The View of the Cardiologist Dr. Yael Peled, Cardio-Oncology Interactions: 1.Cardiotoxicity following chemotherapy 2. Co existence of cancer and CVD Aging & common risk factors cardiac
More informationEvolving Insights into Adjuvant Chemotherapy. Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology
Evolving Insights into Adjuvant Chemotherapy Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology 80 70 60 50 40 30 20 10 0 EBCTCG 2005/6 Overview Control Arms with No Systemic
More informationPolicy No: dru281. Medication Policy Manual. Date of Origin: September 24, Topic: Perjeta, pertuzumab. Next Review Date: May 2015
Medication Policy Manual Topic: Perjeta, pertuzumab Committee Approval Date: May 9, 2014 Policy No: dru281 Date of Origin: September 24, 2012 Next Review Date: May 2015 Effective Date: June 1, 2014 IMPORTANT
More informationAdjuvant chemotherapy in older breast cancer patients: how to decide?
Adjuvant chemotherapy in older breast cancer patients: how to decide? H. Wildiers University Hospitals Leuven Belgium Wildiers H, Kunkler I, Lancet Oncol 2007 Biganzoli L, Wildiers H, Lancet Oncol. 2012
More informationUpdate from the 29th Annual San Antonio Breast Cancer Symposium
Update from the 29th Annual San Antonio Breast Cancer Symposium The San Antonio Breast Cancer Symposium is one of the most important breast cancer conferences. Approximately 8,000 physicians, oncologists,
More informationDR LUIS MANSO UNIDAD TUMORES DE MAMA Y GINECOLÓGICOS HOSPITAL 12 DE OCTUBRE MADRID
DR LUIS MANSO UNIDAD TUMORES DE MAMA Y GINECOLÓGICOS HOSPITAL 12 DE OCTUBRE MADRID RESUMEN DE ARTICULOS THERESA BOLERO 3 NOAH UP-DATE GEPAR SIXTO RADIOTHERAPY EBCTCG CTCs MISCELANEAS Lancet Oncol 2014;
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Health Technology Appraisal Trastuzumab, as monotherapy and in combination with a taxane, for the treatment of metastatic breast cancer (to include
More informationSetting The setting was secondary care. The economic study was carried out in Canada.
Anastrozole is cost-effective vs tamoxifen as initial adjuvant therapy in early breast cancer: Canadian perspectives on the ATAC completed-treatment analysis Rocchi A, Verma S Record Status This is a critical
More information